Chaidari

• Apremilast study in children with active oral ulcers associated with Behçet's Disease Ended recruitment
  2023-503436-40-00 5 2024-11-11 Oral ulcers associated with Behçet’s Disease
• A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-510584-37-00 4 2024-10-22 Systemic Lupus Erythematosus
• A research study to evaluate the effects of a new oral medicine called cenerimod in adults with systemic lupus erythematosus Ended recruitment
  2024-515870-28-00 5 2024-10-22 Moderate to severe systemic lupus erythematosus
• HARMONi-3 Ended recruitment
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulm … Ended recruitment
  2024-511330-13-00 4 2023-01-17 Idiopathic Pulmonary Fibrosis
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin … Ended recruitment
  2023-505695-30-00 5 2021-11-30 systemic lupus erythematosus
• A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects … Ended recruitment
  2023-506094-35-00 3 2021-09-17 Newly diagnosed aggressive B-cell lymphoma (a-BCL)
• Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended recruitment
  2024-512978-99-00 4 2021-07-19 Chronic graft versus host disease (cGVHD)
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended recruitment
  2022-501817-29-00 5 2018-11-27 High Risk Non-muscle invasive bladder cancer
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a … Ended
  2024-510779-39-00 4 2018-12-19 Neoplasm

Showing 121–138 of 138 trials